Malviya V K, Deppe G, Boike G, Young J
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Hutzel Hospital, Detroit, Michigan 48201.
Gynecol Oncol. 1990 Feb;36(2):185-8. doi: 10.1016/0090-8258(90)90170-p.
The pharmacokinetics of intraperitoneal doxorubicin in three previously untreated patients with ovarian cancer are described. All patients were maximally cytoreduced (largest residual tumor less than or equal to 2 cm). The average total body clearance (TBC) was 16.3 ml/kg/min (range 10.6-20.4 ml/kg/min) and the mean volume of distribution (VD) was 42.4 liter/kg (range 27.6-46.9 liter/kg). Half-life of elimination (t 1/2 beta) was 2.6 hr. In spite of a therapeutic advantage of 60 when administered intraperitoneally, prohibitive local toxicity limited the use of doxorubicin via the intraperitoneal route in patients with ovarian cancer.
描述了三名未经治疗的卵巢癌患者腹腔内注射阿霉素的药代动力学。所有患者均接受了最大限度的肿瘤细胞减灭术（最大残留肿瘤小于或等于2厘米）。平均全身清除率（TBC）为16.3毫升/千克/分钟（范围为10.6 - 20.4毫升/千克/分钟），平均分布容积（VD）为42.4升/千克（范围为27.6 - 46.9升/千克）。消除半衰期（t 1/2β）为2.6小时。尽管腹腔内给药时具有60倍的治疗优势，但严重的局部毒性限制了阿霉素在卵巢癌患者中通过腹腔途径的使用。
